Member Info for Saxondale

Yep still early days at Artemis there . Lots of drilling planned ,and the distances between their drills could fit a Havieron in .
At least for GGP there is another company drilling holes in the close vicinity , so it all helps .
They have six large targets to go at in 2022 . They've only just started.
Just scratching the surface , to dig out that well used phrase lol .

And like Paddy says , it makes you appreciate how fantastic it is to get world class drill assays virtually every time they put a hole in the Hav system .

I moved a fraction of my GGP holding over here when they listed . Just added a bit more at 3.3p .
Lots of news to come , and assay results will be dropping soon too .
Just take advantage of the lull .

Last chance to buy in single digits perhaps .
Either people are betting on good news coming , or I'm hoping its actually that some people know that good news is coming .
EML been very positive recently on social media .
I know that's their job , but why set yourself up for a fall .
If this permit lands now - they are in a perfect set of conditions ( unfortunately) to make the most of it .

proper link -
https://aacrjournals.org/mct/article/doi/10.1158/1535-7163.MCT-21-0840/696262/Nonclinical-characterization-of-bexmarilimab-a#.YnAqZ_cZNWU.twitter

New research published by Hollmen lab regarding the workings of Bex , and how detailed analysis confirms how and why it works .

Passage below discusses dosing - something that they are finalising . Looks from this that as Bex seems to get cleared from the system fairly quickly ( explaining the soluble Clever 1 re-emergence during the 3 weekly dose intervals ) , perhaps a clue that a lower dose given more frequently will be the way to go ?
They will be getting clinical human data now from the more frequent dosing regimes , so hopefully not long to put it all together .
Great work by Hollmen Lab anyway - working to really build the picture of Bex .

The pharmacokinetics in cynomolgus monkey suggest that bexmarilimab is cleared relatively fast
from the circulation and thereafter Clever-1 is no longer occupied on circulating monocytes. Clever-
1 is a scavenger receptor, and it is expressed not only on monocytes, which are quite abundant in
the circulation but also on the hepatic sinusoids. Thus, the receptor mediated clearance can be quite
fast. This accompanied with the modest affinity to the FcRn may significantly affect the clearance
of the antibody from the circulation. The exposure of bexmarilimab over time is not dose
proportional. These data suggest that either high doses or frequent administration with small doses
would be required for sustained Clever-1 receptor occupancy if the pharmacokinetics in humans are
similar to those observed in cynomolgus monkey.
Taken together, it can be concluded that bexmarilimab could induce an immunostimulatory tumor
microenvironment that leads to anti-tumor efficacy without suspected major safety concerns.
Bexmarilimab binds to Clever-1 and inhibits the internalization of its ligands without impairing
bacterial uptake but does not bind to Fc?Rs, complement components, or non-target tissues, and
does not induce excessive cytokine production in normal or healthy tissues. This suggests that there
is a solid rationale for the continuing development of bexmarilimab for the treatment of difficult-to-
treat cancers by providing permanent immune stimulation through targeting myeloid cell function.

https://watermark.silverchair.com/mct-21-0840.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAtwwggLYBgkqhkiG9w0BBwagggLJMIICxQIBADCCAr4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM5bOT3qeoSGfaK_APAgEQgIICj6vvrV91WP7Zev-IkX-gLyT9wlGuoOPhpT6KkJVvFvhRwV0SMc8fSVsequG6wGiTpu4s7xAI8RMhKliDiafFjfIyPwSAO16ywBTFp0-Oe2pEknza0BRdXq1Ctb_4Bi9atFKoG8Lo446s8FPaY_NsRBuYhrJKMpVEZPyoBSbTEFavEEf1Re1ZaNf4p_crhRetmIlOBcbvlGI03EQTDtPvkOYewnYdr5x9F1rXS5lUqAFXRHaA0L9AzgQXcAstXh-OLTvupXyaxydAlA7lczMd7xOGvX5q7BgR5BbFI0wwXEPNmSUpooCqCcL1b10p6Mgtlzd5nnZhwmpz8IjOHTypBCdrn-DQBsAaF4zjFkJK6Zbxjay37U2l5JqzKtKakTW2xPDNwFZYEpnujuSYESV74jJooD96t4WRoFZf_HRQOvmmILrd_cdIWW_uPPTq7HmBak0mc5CYdxoi3sjUpIR8rKx41S5GJTrzJ8fRptkbPaER6XJVpxAUDPv9vQtjYQH9D4FXtAJ-mkqqRAD0q0TI9YhB0jMTMwEZoTliC7TAd_F4GA2c1bxZ4imEcVz1byphI54yFgWPkNkBMJxBHKjm

Orion Capitols Simon Francis did a good analysis a month ago , and valued EML near term of 46p later this year ( 30% of its NPV ) . Currently trading at 3% of NPV .
£1.10 valuation once production starts in a year or so .
https://www.youtube.com/watch?v=3NzBfdiokdg

Add into that the rising Potash price , and supply problems - it just gets better .

But as usual , its the paperwork & politics that can make or break these projects - so nothing's guaranteed .

Sorry , the SP has actually risen a fair bit recently , just in a slow steady way that you don't really notice .
The potential here is massive . Lets hope it all unfolds the way we want .

Hello 9p ! Wow this share has taken its time , but maybe we are on the way now ?
Been here for a fair while . I love the positive twitter vibe that EML put out , but it hadn't helped the SP much .
If this gets anywhere near the analysts forecast , should be well worth holding on to these .

Just catching up here too . Watched the SD interview . Great again , and signals that he is on it 100% .
Another bonanza drill result set .
Wasn't expecting fireworks with SP as usual .
Just gives me more time to add when possible .
So exciting to now to see these growth areas throwing up world class results , just adding to our basket of gold !
Decades of production , and all these rigs drilling away as we speak , trying the find the edges of this monster find .
Can't grumble at that .

These two posts have an application period ending 2nd May .
I overlooked the vacancies , thinking the IR post was filled . But that was the US one . This one is for Europe , so they sure are building up a full team .
And the Finance manager really does point specifically to US IPO .

But like others have said , Markku and the team are heavy share holders .
The wheels have been turning for a while now , and no doubt they will have a plan to roll out this IPO alongside some positive developments . They won't be doing this lightly .
I 100% trust in them doing whats best for shareholders .

Just watched the AGM presentation .
Standout comments -
1.) Wall St . Ready - Toni will be working alongside Erik in the US on compliance matters in preparation to access the US capital markets . They have a new Vice president of Investor Relations now hired and starting on 1st May .
So couldn't make it any clearer that they intend to list in the US . Toni also thanked the EIC , who have made multiple funds available and for choosing Faron as the first company that they have taken an investment position in .
2.) Big Pharma discussions - after saying that these kind of treatments can command multi billion deals , Markku says ' I am happy to say that a number of companies are discussing with us ' 'this really is a significant opportunity for us ' .
There was no need to say this - but you can tell from that comment that we are past the $100-200m dollar sort of discussions . We are getting into the realm of big buck deals now .
3.) Bex data - highlighted how the fact that these refractory patients are still alive after 12 months is remarkable , but in addition , the fact they are still alive gives Faron the opportunity to glean more and more data from them . The staining diagnostic on the tumours is showing clinical benefit , and they expect to release further data on this in Q2 ' rather soon '.
Bexmab - this trial is again getting underway - with news coming ' rather soon' . With a survival rate of only 10% after 5 yrs of diagnosis , Bex could make a huge difference here .
Bexcombo - this basket trial is getting them excited as slides showed the potential benefit of Bex with PD-1 blockade treatments being able to tick all the relevant boxes to benefit patients .
4.) Traumakine - multiple options of externally funded trials to go forward with . News to come
5.) Haematokine - straightforward stem cell science - that they hope to announce something in this area soon .

All in all , a very positive and exciting outlook .
Markku apologised for continuing to ask investors to 'wait' , but explained that with having such success with patients and having the ability to gather more data with survivors , it will pay dividends in the long run.

As a long term investor , what more could you ask for . They are pushing on with the science , they are hiring team members both for trials , and to gain access to the US markets . They are adding advisory members , and have secured funding to see them through this period whilst discussing licensing deals with a 'number' of Big Pharma companies .

Compared to previous presentations - this one highlights how close we are getting to the money .
Amazed that the SP is where it is . But then again , the market is a strange beast . I've seen it before , when rerates happen out of the blue almost . But in this case there are so many breadcrumbs being left as to where this is heading , I'm amazed more people haven't cottoned on to it .

To have 100 % of these end of line patients be alive a year later , when only a third of those that didn't were , would normally be a situation where you could possibly apply for an EUA .

To be blunt , the odds are stacked against you , even if your therapy is effective .
Many cancer drugs at this end of the patients life , often will be classed as a success if they can give 3-6 months extra life.
To make this difference should be an real eye opener.
I will be interested to see how the market responds to this .

And with this success , surely they will gain access to earlier stage patients . It sounds crude , but there must be huge competition for access to these folk , so I guess you need to prove yourself worthy before being moved up the food chain .

The beauty of Bex is that it isn't a kill or cure drug . A failed patient can move on down the line . No severe side effects , and with this easy blood test to determine biomarkers , the selection process is simple . So access to early stage patients , or even as a neoadjuvant should be encouraged .

But the crux of the matter is that we aren't just a therapy . We are the 'catalyst' , the primer , the activator , that can make these other immunotherapies become effective in patients where otherwise they may score a dud .

PS I've still got all my SNG shares . Just letting them get on with their deep dive , and see what comes out of it . I can't add much to the conversation over there , but I'm still 100% committed .

Also of note is the comment below - stating how these patients providing these excellent results are not fresh arrivals , but patients a long way down the road , having had many treatments already , and failing to respond . Their immune systems are probably already well compromised , so for Bex to have such success here is even more remarkable .

Imagine the success rate on earlier stage patients with a more intact immune response to ignite . And when the dosing regime is properly sorted to have maximum benefit .

"This rate of clinical benefit is particularly striking when you consider these are heavily pre-treated patients, all of whom were refractory to currently approved checkpoint inhibitor therapy," said Marie-Louise Fjällskog, M.D., Ph.D., Chief Medical Officer of Faron. "Bexmarilimab's ability to ignite an immune response in these patients means that it may serve as a catalyst for the immune system allowing initially checkpoint inhibitor resistant patients to become responsive to PD-1/L1 blockade."

Interesting development here .
In the latest releases up till now , the overall Bex responder survival rate was 70% compared to 26% for non responders , and that was over 9 months .

Here in this cohort , the Melanoma cohort has survival rate of 100% for Bex responders , against 33% for non responders , over a period of 12 months !

So looks like the data is even more compelling .
The biomarker data is standing up , as is the IFN Gamma levels being raised as predicted.

Should get a very warm reception from the audience , for whom this cohort is their specialist area .

Looking good - probably won't budge the SP an inch knowing our luck , but one day it'll blow lol .

Oh well , we are where we are . At least the company is in a better place , they are building up the program , and we can't fault them with that .
Looks like they are doing some kind of interview/forum regarding that Red Eye report next Tuesday .
https://www.redeye.se/events/835773/investor-forum-online-redeye-initiate

Cov , if you look at other small pharma companies , you'll see that the market often doesn't wait for commercialisation to rerate the SP . Sentiment , increased interest and speculation can catapult a share price well above its expected target price well before it is actually realised .
Take AVCT for example . Hardly sold a Covid test , yet the SP sky rocketed on sentiment and future potential . Obviously it can also crash back down to earth just as fast ( as it did ). 4D Pharma also , again , rose hugely , just on speculation . AVCT risen again this month on therapy hopes . Doubled in a few weeks . Still in Phase I , but speculation and interest has pushed the SP up .
With both of those shares , an investor could have bought , waited a bit , and sold , made great money , without either company even getting a drug to market .
Faron has a very small free float in percentage terms . Lots of sticky hands . Not many traders .
We just don't have that speculation of interest yet to put pressure on the SP .
But the catalyst that starts us moving could land any day .

If things go to plan , by the time Faron makes a Big Pharma deal with Bex , we will have had a lot more news regarding trials , US set up , possible Wall st listing ,dosing , soluble clever 1 , financing , Traumakine and probably Haematokine .

You may have a chance to exit with profit before 2 years are up .

Mind you , you may not too . Nothing in life is certain .

This Red Eye report is on one hand a bit dour and dull .
On the other hand , its something that II's like to look at , and justify investments .
The fact that this has even been produced , is a signal that Faron is being weighed up as a contender .

We have never had a broker target for Bex . This is as close as we have now to a first stab at putting a valuation on it .

Don't worry too much about the timelines , nothing is that predicatble .

Very detailed report , although they are only working on the premise of what data we have so far .

They show Bexmab as expecting topline data in 2024 , but Markku said that they will know very quickly if the drug is working , almost as soon as first patient is dosed . That could happen in the next quarter .
News of that could then accelerate licensing / market approval - and boost the SP .

News of dosing and soluble Clever 1 could also be a catalyst for SP reaction .

Traumakine trials / DofD deal could also be a boost .

Although this kind of report is a great accountants viewpoint , things can change very rapidly when new data emerges .

I think these guys have produced a great report , but when you have a cancer drug that is breaking new ground , with so many potential offshoots , pinning a £ figure to the drug is not that easy .

I don't think anyone would be happy selling all their shares for £10 or euros .

Still , considering we are at £2.30 , at least their conclusion is that we are a very well run company , with huge potential , great management and a exciting pipeline .

I've been singed around the edges a few times here. In at 50p , out slightly lower , in at 25p , out considerably lower .
So back in at 11.5p this morning .
Third time lucky I'm hoping .
So far so good - but not opening the champagne quite yet .

We consider both Faron’s management team and ownership as positive components in the investment case. Dr.
Markku Jalkanen, being the CEO and a co-founder of the company, is a solid cornerstone of the company. Alongside
him we see a management team and Board of Directors with extensive experience and sector expertise to drive the
company’s projects forward and generate shareholder value. Further, we are encouraged by the company’s strong
and concentrated ownership structure, featuring institutional investors and long-term-oriented shareholders.

At present, Faron is a pre-revenue biotech company in research and development stage. Consequently, the company
is highly dependent on capital markets for near-term funding and potential licensing partners for future late-stage
development. However, the future sales potential for, primarily, Bexmarilimab is truly enormous. Our sales model
estimates global annual peak sales of more than USD 4.3bn. Should the candidate further demonstrate significant
clinical benefits in ongoing and upcoming trials, we believe a licensing deal with a Big Pharma company is realistic
and would create considerable shareholder value.

Thanks Doku , wow that sure is an in depth report .